drugset
drugset / Trial / NCT01661790

Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer

NCT01661790 ↗

Phase 3 Completed 72 enrolled Chinese PLA General Hospital Roche Pharma AG · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

To determine the efficacy and Safety of intrapleural Bevacizumab and cisplatin as a treatment for malignant pleural effusions (MPE) in patients with non-small cell lung cancer (NSCLC).

Timeline

Start
2009-08
Primary completion
2012-06
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 300 mg Other
Subject Cisplatin Other / unclassified 30 mg Other

Indications

pleural neoplasm